Genetic screening of newborn in Australia. Results for 1981

Area of Science:

• Medical Genetics
• Public Health
• Neonatal Screening

Background:

• Newborn screening programs are crucial for early detection of genetic disorders.
• The Guthrie bacterial inhibition assay has been a cornerstone of neonatal screening since the 1960s.

Purpose of the Study:

• To report the cumulative data and incidence of screened newborn infants for several genetic disorders in Australia.
• To provide updated statistics on phenylketonuria (PKU), malignant hyperphenylalaninaemia (MHPA), congenital hypothyroidism, galactosaemia, and cystic fibrosis.

Main Methods:

• Retrospective analysis of newborn screening data collected across Australia.
• Utilized the Guthrie bacterial inhibition assay for PKU and MHPA screening.
• Data collection included incidence rates per 10,000 live births for each condition.

Main Results:

• Over 3 million infants screened for PKU, detecting 251 cases (0.83/10,000) and 6 MHPA cases (0.02/10,000).
• In 1981, 11 PKU cases were identified.
• Screening for congenital hypothyroidism in seven states detected 66 new cases (2.13/10,000) in 1981.
• Galactosaemia screening in Adelaide identified 7 cases (0.45/10,000) out of 154,310 infants.
• Cystic fibrosis screening in New South Wales found 17 cases (4.73/10,000) among 35,955 infants.

Conclusions:

• Newborn screening programs in Australia have successfully identified significant numbers of infants with serious genetic disorders.
• The data highlights the ongoing importance and effectiveness of widespread neonatal screening for early intervention and management.
• Continued surveillance and reporting are essential for monitoring disease incidence and program efficacy.